CORDIS European Research Coordinated by TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY Israel ENG

How can you cooperate with a genocidal state, as if nothing were happening?

Volatile biomarkers for schizophrenia management

Schizophrenia affects approximately 1 % of the global population, with a misdiagnosis rate ranging from 23 % to 40 %. The EU-funded VOLABIOS project aims to enhance schizophrenia management via the detection of volatile organic compounds (VOCs) in breath, urine, blood and skin as non-invasive biomarkers for early diagnosis. The project will conduct clinical studies involving subjects across six centres and a blind validation study with at-risk individuals. By combining VOC analysis with genomics, proteomics and transcriptomics and supported by a biobank of 4 000 samples and a dataset of 9 million records, the project seeks to uncover factors contributing to schizophrenia and improve diagnostic accuracy. Ultimately, VOLABIOS aims to pave the way for earlier diagnoses and better patient care.

EU contribution € 7 988 082,73

Prevention and Early detection of Schizophrenia. Validation and Comparitive Multi-Omics Benchmarking of Fluid-Derived Volatilomics Biomarkers.